The longest runway in the base-editing race — and the right metric for a pre-revenue biotech.
↓ scroll to read
✦ The bottom line
Beam ended Q1 2026 with $1.2 billion in cash, equivalents, and marketable securities — including $100M drawn from a Sixth Street credit facility. Management says that funds operating plans into mid-2029. For a biotech that burns ~$345M a year, that's about three years of runway.
↓ the brief below
✦ Teach me
Why biotech runway gets measured in years, not months
Drug development takes time — trials run for years, regulatory review for months more. A biotech needs enough cash to fund the trial AND wait for the readout AND prepare for commercialization. Three years of runway is considered comfortable. Two years is tight. One year means the company will likely be raising before then — at whatever stock price exists at the time.
Wall Street calls this
Biotech cash runway
Runway determines whether Beam can fund its trials to readout — *without* needing to raise stock when prices may be unfavorable.
The cushion · cash position
$1.2
B
$1.2 billion in cash, equivalents, and marketable securities at quarter-end — roughly flat versus year-end after a $100M draw from Sixth Street and another $100M expected.
The burn rate is the other half of the equation. Beam used $129 million of operating cash in Q1 2026, on a path to roughly $500M+ for the full year — heavier than 2024's $347M as more programs entered the clinic. That trajectory needs to plateau, not keep climbing, for the mid-2029 runway to hold.
The drain · Q1 operating cash burn
-$129
M
Q1 operations used $129M of cash — annualizing to over $500M as the pipeline scales. Management's runway projection assumes the burn doesn't keep accelerating.
Source · 10-Q · Statements of Cash Flows (operating activities) · Q1 2026 · Filed May 7, 2026
⚠
Watch
Three years of runway buys time to get drugs to market — but Beam is still pre-revenue from product sales.